Last reviewed · How we verify
STR001-IT and STR001-ER
STR001-IT and STR001-ER are glucagon-like peptide-1 (GLP-1) receptor agonists.
STR001-IT and STR001-ER are glucagon-like peptide-1 (GLP-1) receptor agonists. Used for Type 2 diabetes, Type 2 diabetes with obesity.
At a glance
| Generic name | STR001-IT and STR001-ER |
|---|---|
| Sponsor | Strekin AG |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
They work by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. This is achieved by binding to the GLP-1 receptor, which stimulates the release of insulin and inhibits the release of glucagon. This results in improved glycemic control and weight loss.
Approved indications
- Type 2 diabetes
- Type 2 diabetes with obesity
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |